KTKudakwashe Collins Takarinda

Kudakwashe Collins Takarinda

*This is an algorithmically generated author record based on publicly available information.

Kudakwashe Collins Takarinda has a total of 249 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeted HIV Testing Modalities in Zimbabwe: Achieving Effectiveness through a Revised Model

    by Hamufare Dumisani Mugauri, Owen Mugurungi, Joconiah Chirenda, Kudawashe Takarinda, Mufuta Tshimanga

    Introduction: HIV testing remains central to epidemic control, yet status awareness in Zimbabwe remains below UNAIDS targets. We evaluated a targeted testing model integrating risk screening with optimized index testing.Methods: We conducted a convergent mixed-methods study across eight provinces, April 2021-June 2022. A five-question HIV risk screening tool was evaluated, screen‑negative clients were offered HIV self-testing or scheduled testing. Performance metrics included sensitivity, specificity, positive predictive value, and number needed to test (NNT). Twenty in-depth interviews with healthcare providers were conducted in sampled primary, secondary and tertiary facilities to explore implementation enablers and barriers. Index testing was assessed through cascade analysis of 6,308 index cases across 50 facilities, using logistic regression to identify predictors of positivity. Programme fidelity was evaluated using a logical framework.Results: The screening tool achieved 94.1% sensitivity, 65.8% specificity, and reduced testing volume by 18.0% (NNT=11). In the Index testing cascade, 66.4% of index cases were offered testing; of 5,080 elicited contacts, 78.6% were tested, yielding 56.5% positivity and 91.8% linkage. Predictors of positivity included anonymous tracing (aOR 8.46; 95% CI 3.37–22.75), testing within seven days (aOR 2.78; 95% CI 2.44–3.18), male sex (aOR 3.09; 95% CI 2.74–3.49), and first‑time testers (aOR 1.65; 95% CI 1.43–1.91). Programme fidelity ranged from 62.2% to 81.8%, with barriers in SOP use, staffing, and tools.Conclusion: This comprehensive evaluation of Zimbabwe’s targeted HIV testing strategy demonstrated that combining a validated screening tool with optimized Index testing improves efficiency, yield, and linkage. The output (revised model) informed national guidelines review.

  • Open Access

    Integrating status-neutral and targeted HIV testing in Zimbabwe: A complementary strategy

    by Hamufare D. Mugauri, Owen Mugurungi, Joconiah Chirenda, Kudakwashe Takarinda, Prosper Mangwiro, Mufuta Tshimanga

    Introduction: Zimbabwe exclusively implemented targeted HIV testing until 2022 when Status-neutral testing was embraced. Whilst targeted testing aims to expand access and uptake of testing among high-risk individuals, status-neutral testing emphasizes post-test linkage to prevention and treatment services. To address how the two concepts relate in practice, we explored how status-neutral and targeted testing concepts correlate, in developing a double-edged strategy for effective case identification and linkage to prevention and treatment. Methods: We conducted a cross-sectional study on 36 multi-stage sampled sites across 4/10 provinces of Zimbabwe. A national screening algorithm was used to determine patient risk profiling and eligibility for testing. Screened-out patients were offered HIVST. Both screened and non-screened patients were tested and analysed for positivity ratios and linkage to post-test services. Epicollect5 was used to collect data and analysed using EpiData software and Stata. Univariate, bivariate and multivariate analyses were conducted at a 5% significance level. Results: Of 23,058 HIV tests done, females constituted 55% (n = 12,698), whilst 63.5% (n = 14,650) were retested. Through screening, at-risk patients contributed 75.1% to the overall positivity (1,296/1,727), from 66% (n = 15,289) of the total HIV tests conducted. All screened-out patients were non-reactive on HIVST: 1,182/1,182. The 45–49-year category was 3.6 times more likely to test positive (a95%CI:2.67,4.90). Males were 3.09 times more likely to test positive in adjusted analysis (a95%CI: 2.74, 3.49). First tests were 65% more likely to test HIV positive (a95%CI: 1.43, 1.91) whilst screened patients were 3.89 times more likely to link to HIV prevention services (a95%CI: 3.05, 4.97), against 25.5% (n = 1,871) linkage among patients not screened. Conclusion: The complementarity of the status-neutral and targeted testing approaches is evident from our results. By prioritizing high-risk individuals for testing and ensuring comprehensive linkage to both prevention and treatment services, these integrated strategies can effectively identify and manage people living with HIV. This combined approach optimizes resource use, particularly in low- and middle-income countries, and contributes to improved health outcomes and reduced HIV transmission rates.

  • Faculty Opinions recommendation of Residual respiratory disability after successful treatment of pulmonary tuberculosis: a systematic review and meta-analysis.

    by Anthony Harries, Kudakwashe C Takarinda

    The interest in pulmonary disability following the successful completion of tuberculosis (TB) treatment continues to grow. The authors of this paper conducted a systematic review and meta-analysis of studies between 1960 and 2022 evaluating respiratory impairment, disability status, and respiratory complications after successful completion of TB treatment. There were 61 included studies with a total of 41,014 participants. The key findings were as follows: 59% of participants with pulmonary TB had abnormal pulmonary spirometry compared to 5% of controls Specifically, 18% had obstruction, 21% had restriction, and 13% had a mixed pattern The mean 6-minute walking distance was 440.5 meters, markedly lower than predicted scores of exercise capacity There was a four-fold higher increase in lung cancer compared with controls Common post-treatment complications included cavitation, fibrosis, bronchiectasis, and aspergilloma This review highlights the important post-treatment ongoing morbidity caused by pulmonary TB and demonstrates that pulmonary TB is a major cause of disability worldwide. In turn, the review findings emphasise the importance of preventing TB in the first place and the important benefits of TB preventive therapy in high-risk individuals.

  • Faculty Opinions recommendation of Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial.

    by Anthony Harries, Kudakwashe C Takarinda

    In sub-Saharan Africa, health care for chronic conditions is usually fragmented and delivered through a vertical approach. HIV care is provided through dedicated HIV clinics, with patients managed separately from those with other chronic conditions such as diabetes mellitus and hypertension. Health policies in sub-Saharan Africa now recommend integrated healthcare provision, but to date, there has been no published evidence from randomised controlled trials to support this practice. There is also concern from HIV care providers that integrated care may lead to worsening of HIV management. To address these issues, a cluster randomised trial was undertaken in Tanzania and Uganda to determine whether integrated care for HIV, diabetes and hypertension compared with standard care was superior in terms of retaining people on treatment for diabetes and hypertension and non-inferior in terms of viral suppression among those with HIV infection. There were 32 facilities that participated in the study, allocated in a 1:1 ratio to either integrated care or standard care. In the integrated care group, participants with HIV, diabetes or hypertension attended a single clinic. They were managed by the same healthcare workers and used the same laboratory and pharmacy. In the standard care group, participants attended separate stand-alone clinics for HIV, diabetes or hypertension, with different healthcare workers and different laboratories and pharmacies. There were two coprimary endpoints: i) retention in care for participants with either diabetes or hypertension (defined as attending the clinic within the last 6 months of study follow-up) and ii) plasma viral load suppression for those with HIV (defined as viral load <1000 copies per mL). Altogether, there were 7023 eligible participants (adults aged 18 years or older living within the catchment area) allocated to either integrated or standard care. Follow-up lasted for 12 months. Among those with diabetes, hypertension or both, 89.0% of 1409 participants were retained in integrated care, which was no different to 89.8% of 1623 in standard care. Among those with HIV, plasma viral load <1000 copies per mL was 97.0% in 1456 participants in integrated care, which was no different to 97.3% of 1491 in standard care. This was a well-conducted study with no major limitations. The findings showed a high degree of retention in care for those with diabetes, hypertension or both and excellent viral load suppression in both integrated and standard care. Previous studies have shown that retention in care for participants with diabetes, hypertension, or both rarely exceeds 50%, so why were there such good results in this study? The authors suggest two possible reasons: i) participants who missed appointments in both arms of the study were actively traced and encouraged to re-attend the clinic, and ii) there was extensive engagement with key stakeholders before, during and after the trial had ended. This suggests that small changes to non-communicable disease programmes, taken from experiences gained in HIV control, could have important benefits for the management of non-communicable diseases in sub-Saharan Africa. The study also shows that integrated care can work well and does not compromise HIV care and management. A good Editorial accompanies the original research study {1}. Clinical trial details: ISCRTN43896688.

  • Faculty Opinions recommendation of Survival of people with untreated TB: effects of time, geography and setting.

    by Anthony Harries, Kudakwashe C Takarinda

    In 2021, it was estimated that 40% of people who developed tuberculosis (TB) were not diagnosed or treated. What is the likely survival of such patients? This current study used pre-chemotherapy studies that recorded mortality and natural recovery outcomes to estimate TB mortality rates and TB survival rates overall, by geographic and temporal context and in relation to whether patients were placed in sanatoria or not. Survival data were extracted from pre-chemotherapy papers reporting TB-specific mortality and/or natural recovery. Bayesian parametric survival analysis was used to model survival distributions, stratified by geography (North America versus Europe), time (pre-1930 versus post-1930) and placement or not in a sanatorium. Altogether, there were 12 studies with 17,166 patients reporting TB-specific deaths. Overall, 93% of patients survived 1 year and 55% survived 10 years, with a median survival time of 12.3 years. Ten-year survival estimates were as follows: North America – 69%; Europe – 36% Pre-1930 – 50%; post-1930 – 60% Sanatoria-placement – 69%; no sanatoria placement – 38% In summary, reported recovery rates were higher among patients from North America, patients in the post-1930 era and patients placed in sanatoria. The authors noted that better outcomes in North America compared with Europe might have been because North America was more shielded from the worst effects of the two world wars. Also, an increased proportion of North American studies used data from sanatoria. This is an important and well-conducted study. There were a few limitations that included the fact that patients who were moribund were not typically admitted to sanatoria, thus creating some sampling bias, there were no published studies from Africa or Asia, and the data did not account for the impact of HIV, all of the studies being from the pre-HIV era. Nonetheless, these findings from the pre-chemotherapy era can provide important insights that are relevant today. They show that mortality and recovery are dependent on location and setting, and these heterogeneities need to be considered when making inferences about survival of patients today with undiagnosed and untreated TB.

  • Faculty Opinions recommendation of How methodological pitfalls have created widespread misunderstanding about long COVID.

    by Anthony Harries, Kudakwashe C Takarinda

    High rates of long COVID continue to be reported in medical journals, with the prevalence in adult populations varying from 5% to 20% or higher. These high rates are further disseminated by the media and cause immense concern and anxiety in the general public. The authors of the current paper state that many scientific publications overestimate the prevalence of long COVID; they outline the reasons for these mistakes and suggest how future epidemiological research can do a better job. The authors categorize the main methodological pitfalls as follows: Overly broad case definitions. The authors of the current paper define long COVID as a syndrome or individual symptoms that are direct sequelae of being infected with SARS-CoV-2 and last for at least 12 weeks. Existing definitions from four international health organizations (including the World Health Organization in Geneva, Switzerland, and the Centers for Disease Control and Prevention in Atlanta, USA) do not require a causal link between SARS-CoV-2 infection and symptoms, meaning that any new symptoms that occur after confirmed or suspected SARS-CoV-2 infection, regardless of their aetiology, could be considered consistent with long COVID. Moreover, not all these definitions require there to be a laboratory-confirmed infection with SARS-CoV-2. Lack of controls or inappropriately-matched controls. The authors cite one recent systematic review which identified control groups in only 11% of 194 studies on long COVID. Where controls are included, they are often not properly matched to cases such as, for example, by age, sex, geography, socio-economic status and underlying health and health behaviours. Sampling bias. This type of bias occurs when certain members of a population have a higher probability of being included in a study than others. In the early stages of the pandemic, studies were often non-representative because they included fewer patients with mild symptoms or no symptoms at all. Better case definitions and appropriately matched controls will lead to better estimates of long COVID prevalence. The authors found that when they limited studies to those fulfilling these criteria, the prevalence of reported persistent symptoms in children or adults younger than 50 years of age was no different by 12 weeks post-SARS-CoV-2 infection compared with controls. Such high-quality studies stand in contrast to much of what is reported in the media and can, and should, be used to reassure the public about the risks of long COVID.

  • Faculty Opinions recommendation of Outcomes of TB contact tracing and predictors of success: a 10-year retrospective cohort analysis in Birmingham, UK.

    by Anthony Harries, Kudakwashe C Takarinda

    Tuberculosis (TB) preventive therapy given to high-risk populations is one of the key activities that will help end the TB epidemic. In September 2018, at the United Nations High Level Meeting on TB, member states pledged to provide TB preventive therapy to 30 million people over a five-year period between 2018 and 2022. This included 24 million household contacts. However, in the event, only 4.2 (17.5%) million household contacts received TB preventive therapy. Much work is needed to improve this aspect of TB control. Providing TB preventive therapy to contacts of TB cases requires their systematic screening for TB infection and TB disease, and deciding who needs TB treatment and who is eligible for TB preventive therapy. In this context, the current study about TB contact tracing in Birmingham and Solihull, UK, over a ten-year period is of interest. Between 1990 and 2010, less than 60% of contacts of TB cases completed screening for TB infection. The TB health service responded to this poor performance by increasing staff numbers, changing screening locations and increasing screening follow-up. A retrospective analysis was then carried out to determine whether screening completion rates had improved and to identify predictors of screening completion. The retrospective analysis was of all contacts of TB patients (with both pulmonary and extrapulmonary disease) in Birmingham and Solihull, UK, between 1 January 2011 and 31 December 2020. Multiple logistic regression analysis was performed to identify predictors of screening completion. Over the ten-year period, 3,255 index patients and 27,820 contacts were identified. Screening completion improved from 59.1% of contacts (between 1990-2010) to 74.9% overall. Important predictors of screening completion were identified. Contacts more likely to complete screening included: children, contacts of patients with extrapulmonary TB, and contacts who were not household contacts. Contacts less likely to complete screening included: males, contacts with no prior BCG vaccination, contacts with a previous history of TB and contacts who were of non-white ethnicity. This was a well conducted retrospective study showing that screening completion can be improved by making changes to the TB health services and highlighting areas for targeted resource allocation. Further work, including qualitative research and mixed-methods studies, is required to better understand the variations in screening completion rates between different contact groups.

  • Faculty Opinions recommendation of Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial.

    by Anthony Harries, Kudakwashe C Takarinda

    Undernutrition has long been recognized as a potent risk factor for tuberculosis (TB), with higher rates of undernutrition associated with higher risks of developing TB. Modelling studies suggest that nutritional interventions would be cost-effective in reducing TB incidence, but this has not been properly established through randomised controlled trials. Until now! The aptly named RATIONS study in India published in the Lancet is the first randomised trial to assess the effect of nutritional support on TB incidence in household contacts of index TB patients. The study took place in four districts in Jharkhand, India, well known for high rates of TB and undernutrition in its population of 33 million. The design was a field-based, open-label, cluster-randomised, controlled trial with 28 clusters centred around TB units with each having between 80-120 households. Within each cluster, any adult (aged ≥18 years) with microbiologically confirmed pulmonary TB and having at least one eligible household contact was enrolled in the trial. Clusters were randomly allocated to intervention or control groups on a 1:1 basis. In both groups, the index patient received a monthly food package providing 1200 kcal per day, along with daily micronutrient pills. In the intervention group, household contacts received a monthly food package providing 750 kcal per day, along with daily micronutrient pills. The control group received no nutritional support. The cost of nutritional support was approximately USD$13 per month for the index patients and USD$5 per month for adult household contacts (less for childhood contacts). There was a planned follow-up of 2 years, but due to COVID-19 delays in recruitment, only 80% of household contacts were followed for this length of time. The primary outcome was incident TB during the follow-up period. Altogether, there were 5621 household contacts in the intervention group and 4724 household contacts in the control group. The key finding was that 1.7% of household contacts in the intervention group developed TB compared with 2.6% of household contacts in the control group. TB incidence in the intervention group compared with the control group had an adjusted incidence rate ratio of 0.61 (95%CI, 0.43-0.85) for all forms of TB and an adjusted incidence rate ratio of 0.52 (95% CI, 0.34 – 0.78) for microbiologically confirmed pulmonary TB. This translated to a relative reduction of TB incidence of 39% for all forms of TB and 48% for microbiologically confirmed pulmonary TB. An estimated 30 households (111 household contacts) would need to be given nutritional support to prevent one incident case of TB. This was a well-conducted pragmatic study done within the National TB Elimination Programme of India and representative of programmatic cohorts in the country. There were some limitations that included: i) no individualization of food packages and no ascertainment of what was actually consumed by household contacts; ii) inability to exclude food sharing in the control group when the index patient received food packages; iii) no masking of investigators or participants to the randomization; and iv) failure to follow all household contacts for 2 years due to COVID-19 induced enrollment delays. Despite these limitations, the study showed that nutritional support of household contacts was operationally feasible, low cost and effective. This intervention should be considered as an integral component of multisectoral strategies to accelerate the reduction in TB incidence in countries faced with a dual burden of TB and undernutrition. An excellent Commentary accompanies the original article {1}. Trial registry details: CTRI/2019/08/020490

  • Faculty Opinions recommendation of The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review.

    by Anthony Harries, Kudakwashe C Takarinda

    Viral load testing is the gold standard for monitoring the response to antiretroviral therapy (ART) in people living with HIV (PLHIV). Viral loads <1000 copies per ml are taken to indicate good adherence to medication and good response to ART regimens, with levels above this indicating possible virological failure. It is generally accepted that viral loads <200 copies per ml are associated with zero risk of sexual transmission of HIV, and this threshold is used for U=U (undetectable = untransmissible) messaging in many high-income settings. The risk of transmission at viral loads higher than 200 copies per ml is controversial. Information on the risk of transmission of PLHIV with viral loads up to 1000 copies per ml, however, is important, particularly in resource-limited settings where measurement of viral load down to very low levels is not feasible due to the use of simple and inexpensive technologies, such as dried blood spots and point-of-care platforms. The current systematic review, therefore, summarized the evidence relating to the risk of sexual transmission of HIV at viral loads <1000 copies per ml. The systemic review identified 244 studies, of which eight were included in the analysis, comprising 7762 discordant couples across 25 countries. Risk of bias using the ROBINS-I framework was low, and the certainty of evidence using the GRADE framework was moderate. Among the documented transmission events, only two were potential transmissions when the index partner’s viral load was <1000 copies per ml. In both these cases, the viral load test was done at least 50 days before transmission occurrence. In stratifying the results, there was no evidence of transmission when viral loads were <600 copies per ml. The authors, along with an accompanying Editorial {1}, emphasise that the findings only pertain to sexual transmission of HIV, and they do not apply to mother-to-child transmission nor to transmission related to sharing of injection drug use equipment. The findings are important for public health programmes in resource-poor areas grappling with the huge burden of ART provision for PLHIV. Viral load measurements should be done at time intervals recommended by the World Health Organization. PLHIV with viral loads <1000 copies per ml can be reassured that not only are their ART regimens working, but their risk of sexually transmitting the virus is almost zero. This messaging can certainly help to reduce stigma and improve quality of life.

  • Faculty Opinions recommendation of The natural history of untreated pulmonary tuberculosis in adults: a systematic review and meta-analysis.

    by Anthony Harries, Kudakwashe C Takarinda

    The natural history of pulmonary tuberculosis (TB) remains incompletely understood. Mortality estimates of untreated tuberculosis have been informed by systematic reviews of the available literature. However, this is not the case for the progression from latent tuberculosis infection to active tuberculosis and regression from active disease back to latent infection. A better understanding of this natural history is important for TB preventive therapy and vaccine development. This systematic review and meta-analysis screened 10,623 titles and abstracts published over a period of 80 years, reviewed 1503 studies and identified 223 studies that met the inclusion criteria (which were any English and German studies that included adolescents or adults with tuberculosis or recent tuberculosis exposure who were followed up for at least 12 months without therapeutic intervention). From these 223 studies, 24 (with 34 cohorts and a combined population sample of 139,063) were included in the review and analysis. The key findings were as follows: For persons with chest x-rays suggestive of active TB, progression from microbiologically negative to microbiologically positive disease occurred at an annual rate of 10% (95% CI, 6.2-13.3) For persons with chest x-rays suggestive of inactive TB, progression from microbiologically negative to microbiologically positive disease occurred at an annual rate of 1% (95% CI, 0.3- 1.8) For persons with normal chest x-rays, progression from microbiologically negative to microbiologically positive disease occurred at an annual rate of 0.1% (95% CI, 0.1- 0.2) Reversion from microbiologically positive tuberculosis to undetectable disease occurred at an annual rate of 12% (95% CI, 6.8-18.0). This was a good study with some limitations that included: i) many studies being done before the discovery of HIV, which is an important determinant of disease progression; ii) the evolution of diagnostic methods, both microbiological and radiological, over an 80-year period; iii) many studies being published over 50 years ago when socio-economic factors, health-care access, association with comorbidities and prevalence of tuberculosis were likely to be different from today; iv) different study designs. Despite these limitations, this systematic review is the first to analyse and report on the kinetics of the natural history of tuberculosis in adults outside of mortality. As such, it provides a much-needed foundation of empirical data about the complex natural history of this ancient infectious disease.